Senate Committee Hearing 110-375, Examining FDA Follow-On Biologics
HEARING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS
UNITED STATES SENATE
ONE HUNDRED TENTH CONGRESS
FIRST SESSION
ON
EXAMINING FOOD AND DRUG ADMINISTRATION FOLLOW-ON BIOLOGICS, GENERALLY REFERRED TO AS A BIOTECHNOLOGY-DERIVED PROTEIN DRUG (OR BIOLOGIC) THAT IS COMPARABLE TO A NOVEL, PREVIOUSLY APPROVED BIOLOGIC AND THAT IS APPROVED WITH LESS SUPPORTING DATA THAN THE INNOVATOR BIOLOGIC
Download the Full Transcript
Tags
biotechnology fda health law policy pharmaceuticals regulation